L'intérêt à découvert pour Novavax donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Novavax. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Novavax (NASDAQ:NVAX) Stock, Rapport sur les intérêts à découvert

Novavax

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

Novavax Inc

NOVAVAX ORD

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 300 points on Wednesday.
The Dow traded up 0.78% to 43,072.45 while the NASDAQ rose 0.32% to 18,374.03. The S&amp;P 500 also rose, gaining, 0.47% to 5,842.65.
Check This Out: <a href="https://www.benzinga.com/markets/24/10/41342689/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter">Top 3 Tech And Telecom Stocks That Could Lead To Your Biggest Gains This Quarter</a>
Leading and Lagging Sectors Utilities shares jumped by 1.6% on Tuesday.
In trading on Tuesday, communication services shares fell by 0.6%.
Top Headline
Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) reported better-than-expected third-quarter results.
The company posted adjusted EPS of $1.88, up from $1.38 a year ago, beating the consensus of $1.58, demonstrating the strength of Integrated Firm with strong results across business segments. Net earnings increased almost 33% to $3.2 billion. The U.S. bank reported third-quarter sales of $15.38 billion, up 15.9% year over year, beating the consensus of $14.41 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>180 Life Sciences Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares shot up 515% to $9.35. 180 Life Sciences interim CEO said that the company is planning to enter the online gaming industry with its newly acquired gaming technology platform.</li>
<li>Shares of Altus Power, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) got a boost, surging 23% to $3.7050 after the company announced that a formal review of strategic alternatives has been underway by its Board of Directors. Also, the company reaffirmed its FY24 guidance.</li>
<li>Versus Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VS#NASDAQ">VS</a>) shares were also up, gaining 304% to $4.5699 after the company announced a $2.5 million investment and licensing agreement with ASPIS.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Service Properties Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVC#NYSE">SVC</a>) shares dropped 17% to $3.9650 after the company announced actions to improve liquidity and reduce leverage. It reduced its quarterly dividend to 1 cent per share.</li>
<li>Shares of Silvaco Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) were down 29% to $7.90 after the company reported a decline in orders from Asia during third quarter and cut its FY24 revenue outlook.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) was down, falling 17% to $10.49 after the FDA placed a clinical hold on the company&#8217;s investigational new drug application for its COVID-19-influenza combination and standalone influenza vaccine candidates.</li>
</ul>
Commodities In commodity news, oil traded up 0.1% to $70.67 while gold traded up 0.5% at $2,691.70.
Silver traded up 0.7% to $31.985 on Wednesday, while copper rose 0.8% to $4.3730.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.19%, Germany's DAX fell 0.27% and France's CAC 40 fell 0.40%. Spain's IBEX 35 Index rose 0.56%, while London's FTSE 100 gained 0.97%.
Asia Pacific Markets
Asian markets closed mostly lower on Wednesday, with Japan's Nikkei 225 falling 1.83%, Hong Kong's Hang Seng Index falling 0.16%, China's Shanghai Composite Index gaining 0.05% and India's BSE Sensex falling 0.39%.
Economics
<ul>
<li>U.S. mortgage applications fell by 17% from the previous week during the second week of October.</li>
<li>Export prices in the U.S. declined by 0.7% month-over-month in September, exceeding market estimates of a 0.4% fall.</li>
<li>Import prices declined by 0.4% from the previous month in September.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41329813/jim-cramer-we-need-more-uranium-recommends-this-stock-says-novo-nordisk-doesnt-hold-a-ca">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41329813/jim-cramer-we-need-more-uranium-recommends-this-stock-says-novo-nordisk-doesnt-hold-a-ca">Jim Cramer: &#8216;We Need More Uranium,&#8217; Recommends This Stock; Says Novo Nordisk &#8216;Doesn&#8217;t Hold A Candle&#8217; To Big Pharma Rival</a></li>
</ul>

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

AMPS

ATNF

NVAX

SVCO

Nasdaq Moves Higher; Morgan Stanley Profit Beats Estimates

<h3>Gainers</h3>
<ul>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock rose 503.9% to $9.18 during Wednesday's regular session. The company's market cap stands at $9.4 million. </li>
<li>Korro Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) shares moved upwards by 124.86% to $89.41. The company's market cap stands at $831.3 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares increased by 111.79% to $0.93. The company's market cap stands at $21.9 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares moved upwards by 84.92% to $0.93. The market value of their outstanding shares is at $3.7 million. </li>
<li>WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) stock moved upwards by 75.23% to $15.0. The company's market cap stands at $2.2 billion. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares increased by 54.07% to $7.72. The market value of their outstanding shares is at $112.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) stock declined by 17.4% to $10.41 during Wednesday's regular session. The market value of their outstanding shares is at $1.6 billion. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock fell 15.27% to $1.16. The market value of their outstanding shares is at $198.1 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares decreased by 11.01% to $0.08. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares fell 9.95% to $8.01. The company's market cap stands at $47.2 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock decreased by 8.61% to $0.47. The market value of their outstanding shares is at $9.9 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock fell 8.58% to $0.31. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BDRX

GNPX

KLTO

KRRO

LGMK

QNRX

RBOT

TVGN

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 250 points on Wednesday.
The Dow traded up 0.59% to 42,994.38 while the NASDAQ fell 0.05% to 18,306.79. The S&amp;P 500 also rose, gaining, 0.19% to 5,826.42.
Check This Out: <a href="https://www.benzinga.com/markets/24/10/41342689/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter">Top 3 Tech And Telecom Stocks That Could Lead To Your Biggest Gains This Quarter</a>
Leading and Lagging Sectors Utilities shares jumped by 0.8% on Tuesday.
In trading on Tuesday, consumer staples shares fell by 0.5%.
Top Headline
U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) posted better-than-expected quarterly earnings on Wednesday.
The company reported third-quarter adjusted earnings per share of $1.03, beating the analyst consensus estimate of 99 cents. Quarterly revenues of $6.864 billion missed the analyst consensus estimate of $6.895 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>180 Life Sciences Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares shot up 713% to $12.36. 180 Life Sciences interim CEO said that the company is planning to enter the online gaming industry with its newly acquired gaming technology platform.</li>
<li>Shares of Altus Power, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) got a boost, surging 15% to $3.48 after the company announced that a formal review of strategic alternatives has been underway by its Board of Directors. Also, the company reaffirmed its FY24 guidance.</li>
<li>Versus Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VS#NASDAQ">VS</a>) shares were also up, gaining 399% to $5.64 after the company announced a $2.5 million investment and licensing agreement with ASPIS.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Bright Minds Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>) shares dropped 37% to $24.24. Firefly Neuroscience collaborated with Bright Minds Biosciences to analyze the data from its positive Phase 1 study using its Artificial Intelligence.</li>
<li>Shares of Silvaco Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) were down 25% to $8.34 after the company reported a decline in orders from Asia during third quarter and cut its FY24 revenue outlook.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) was down, falling 17% to $10.45 after the FDA placed a clinical hold on the company&#8217;s investigational new drug application for its COVID-19-influenza combination and standalone influenza vaccine candidates.</li>
</ul>
Commodities In commodity news, oil traded down 0.2% to $70.46 while gold traded up 0.6% at $2,694.90.
Silver traded up 1.6% to $32.270 on Wednesday, while copper rose 1% to $4.3810.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 gained 0.02%, Germany's DAX gained 0.1% and France's CAC 40 fell 0.17%. Spain's IBEX 35 Index rose 0.75%, while London's FTSE 100 gained 1.15%.
Asia Pacific Markets
Asian markets closed mostly lower on Wednesday, with Japan's Nikkei 225 falling 1.83%, Hong Kong's Hang Seng Index falling 0.16%, China's Shanghai Composite Index gaining 0.05% and India's BSE Sensex falling 0.39%.
Economics
<ul>
<li>U.S. mortgage applications fell by 17% from the previous week during the second week of October.</li>
<li>Export prices in the U.S. declined by 0.7% month-over-month in September, exceeding market estimates of a 0.4% fall.</li>
<li>Import prices declined by 0.4% from the previous month in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41329813/jim-cramer-we-need-more-uranium-recommends-this-stock-says-novo-nordisk-doesnt-hold-a-ca"> Jim Cramer: &#8216;We Need More Uranium,&#8217; Recommends This Stock; Says Novo Nordisk &#8216;Doesn&#8217;t Hold A Candle&#8217; To Big Pharma Riva</a><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41329813/jim-cramer-we-need-more-uranium-recommends-this-stock-says-novo-nordisk-doesnt-hold-a-ca">l</a></li>
</ul>

DRUG

Dow Jumps 250 Points; U.S. Bancorp Earnings Top Views

Novavax Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) stock is trading lower on Wednesday. The FDA has placed a clinical hold on Novavax&#8217;s Investigational New Drug (IND) application for its COVID-19-influenza combination (CIC) and stand-alone <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41355160/update-on-novavaxs-covid-19-influenza-combination-and-stand-alone-influenza-phase-3-trial" rel="noreferrer noopener">influenza vaccine candidates</a>.
The clinical hold is due to a spontaneous report of a serious adverse event (SAE) of motor neuropathy in a single CIC Phase 2 trial&nbsp;participant outside the U.S. who received the vaccine in&nbsp;January 2023.
Motor neuropathy is&nbsp;a condition that occurs when the nerves that control movement are damaged.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38758287/some-breather-for-novavaxs-covid-19-vaccine-inks-multibillion-dollar-deal-with-sanofi-and-erases-" rel="noreferrer noopener">Some Breather For Novavax&#8217;s COVID-19 Vaccine, Inks Multibillion-Dollar Deal With Sanofi And Erases Doubts About Its Going Concern</a>.
The trial was completed in&nbsp;July 2023, and the participant reported the SAE in&nbsp;September 2024.
&#8220;We are working closely with the FDA to provide the necessary information that will allow them to better understand this observation and resolve the clinical hold,&#8221; said&nbsp;Robert Walker, Chief Medical Officer, Novavax.
Data from Novavax&#8217;s previous COVID-19 and influenza trials have shown no signals for motor neuropathy. Investigators have been informed of this action.&nbsp;
The clinical hold does not impact the COVID-19 IND for Novavax&#8217;s COVID-19 vaccine. In April 2022, Novavax announced initial results from the Phase 1/2 trial of its CIC Vaccine.
The preliminary trial results found that various CIC vaccine formulations induced immune responses in participants comparable to reference stand-alone influenza and stand-alone <a target="_blank" href="https://www.benzinga.com/general/biotech/22/04/26721174/novavaxs-covid-19influenza-combo-vaccine-shows-immunogenicity-in-early-study" rel="noreferrer noopener">COVID-19 vaccine formulations</a>.
The company said that the combination vaccine was found to be generally well-tolerated. Serious adverse were rare, and none were assessed as related to the vaccine.
Last week, the European Commission approved Novavax&#8217;s updated 2024-2025 Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2705), dispersion for injection, for use in individuals aged 12 and older to prevent COVID-19&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41246672/novavaxs-updated-2024-2025-nuvaxovid-covid-19-vaccine-receives-authorization-in-the-eu" rel="noreferrer noopener">in the European Union</a>.
Price Action: NVAX stock is down 19.10% to $10.20 during the premarket session at last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41354865/morgan-stanley-q3-earnings-institutional-securities-sees-momentum-total-client-assets-surpass-7-5t-" target="_blank" rel="noreferrer noopener">Morgan Stanley Q3 Earnings: Institutional Securities Sees Momentum, Total Client Assets Surpass $7.5T Across Wealth And Investment Management</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

General

FDA Puts Speed Breaker On Novavax's COVID/Flu Combo Shot Trial On Concerns Related To Damaged Nerves

VS: 489% &#x7C; <a href="https://www.benzinga.com//node/41354474">Versus Systems shares are trading higher after the company announced a $2.5 million investment and licensing agreement with ASPIS.</a>
&nbsp;
NVAX: -32% &#x7C; <a href="https://www.benzinga.com//node/41355032">Novavax shares are trading lower after the FDA placed a clinical hold on the company's investigational new drug application for its COVID-19-influenza combination and standalone influenza vaccine candidates.</a>
&nbsp;
BDRX: 245% &#x7C; <a href="https://www.benzinga.com//node/41354484">Biodexa Pharmaceuticals shares are trading higher after the company announced it successfully appealed Nasdaq's delisting decision and was granted a time extension to demonstrate compliance with its listing rule.</a>

Market-Moving News for October 16th

WIIM

Novavax shares are trading lower after the FDA placed a clinical hold on the company's investigational new drug application for its COVID-19-influenza combination and standalone influenza vaccine candidates.

<h3>Gainers</h3>
<ul>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock rose 183.2% to $14.19 during Wednesday's pre-market session. The market value of their outstanding shares is at $206.0 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock rose 38.87% to $0.48. The company's market cap stands at $10.0 million. </li>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) shares increased by 24.82% to $1.46. The company's market cap stands at $36.8 million. </li>
<li>NovoCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) stock increased by 22.27% to $21.74. The market value of their outstanding shares is at $2.3 billion. </li>
<li>NeuroBo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRBO#NASDAQ">NRBO</a>) shares increased by 17.39% to $2.97. The market value of their outstanding shares is at $25.2 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares rose 16.33% to $0.77. The company's market cap stands at $2.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) stock declined by 19.5% to $10.14 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6 billion. </li>
<li>Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) shares decreased by 18.69% to $15.06. The market value of their outstanding shares is at $95.5 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares declined by 13.67% to $3.16. The market value of their outstanding shares is at $4.2 million. </li>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) shares fell 11.76% to $0.9. The market value of their outstanding shares is at $3.5 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 10.21% to $1.76. The market value of their outstanding shares is at $17.8 million. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) shares declined by 8.86% to $0.54. The company's market cap stands at $6.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABVC

ASMB

CTCX

DWTX

INVO

NIVF

NRBO

NVCR

Tempest Therapeutics, Inc. - Common Stock

TPST

WINT

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Novavax Says On Oct. 11, FDA Notified Co. It Placed Clinical Hold On IND For COVID-19-Influenza Combination And Standalone Influenza Vaccine Candidates Due To Spontaneous Report Of Serious Adverse Event Of Motor Neuropathy

<a href="https://www.cdph.ca.gov/Programs/OPA/Pages/NR24-033.aspx" title="https://www.cdph.ca.gov/Programs/OPA/Pages/NR24-033.aspx">https://www.cdph.ca.gov/Programs/OPA/Pages/NR24-033.aspx</a>

State Reports Six Human Bird Flu Cases Now Confirmed in California ​- CDPH

B. Riley Securities analyst Mayank Mamtani reiterates Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) with a Buy and raises the price target from $23 to $26.

Price Target

Reiteration

Analyst Ratings

B. Riley Securities Reiterates Buy on Novavax, Raises Price Target to $26

Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) on Wednesday announced the receipt of European marketing authorization for its <a href="https://www.benzinga.com/pressreleases/24/10/n41246672/novavaxs-updated-2024-2025-nuvaxovid-covid-19-vaccine-receives-authorization-in-the-eu">Nuvaxovid COVID-19 vaccine</a>.
What Happened: Novavax said the European Commission granted Marketing Authorization for its updated 2024-2025 Nuvaxovid COVID-19 vaccine for use in individuals aged 12 and older.
NVX-CoV2705 is an updated version of Novavax&#8217;s prototype COVID-19 vaccine formulated to target the JN.1 variant. It is a protein-based vaccine made by creating copies of the surface spike protein of SARS-CoV-2 that causes COVID-19.
The European Commission&#8217;s authorization comes after non-clinical data showed that Novavax&#8217;s updated vaccine provides cross-reactivity against JN.1 and several JN.1 lineage viruses.
Novavax&#8217;s 2024-2025 formula of Nuvaxovid has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by the FDA. The Emergency Use Authorization&nbsp;for this product is expected to remain in place for the duration of the COVID-19 Emergency Use declaration.
See Also: <a href="https://www.benzinga.com/news/24/10/41198592/coinbase-nike-and-moderna-are-among-top-11-large-cap-losers-last-week-sept-30-oct-4-are-the-others-i">Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?</a>
<h2 class="wp-block-heading">NVAX Stock Forecast In 2030</h2>
Predicting the future in stock prices over long periods of time is challenging. Wall Street analysts use complex models that take into account interest rates, economic growth, competitive advantages, management teams and historical profitability, among a host of other factors.
If, as an investor, you want to assume most of the major factors remain stable, you can use trend analysis as a helpful tool. Using a longer term trend line or historical performance of the stock, you can aim to forecast a stock's annual rate of return.
For Novavax, over the past five years, its annualized stock performance is 23.39%, and if you assume that trend continues for another 5 years, you can expect a stock to trade at $36.78.
Using a trend line (see how to <a href="https://www.benzinga.com/23/01/30335939/a-guide-on-how-to-identify-trend-reversals">perform this function here</a>), If you choose to use a trend line, connect your two points and look into the future to the point in time in which you're curious. Once you've identified that stock price, you may want to consider what type of conditions would need to exist for the stock to justify the share price &#8211; be it an outside influence or managerial decision making.
NVAX Price Action: <a href="http://benzinga.com/quote/nvax">Novavax shares</a> initially traded up to the $13.60 level before pulling back. The stock was down 0.84% at $12.93 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

What's Going On With Novavax Stock Today?

This decision follows the positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA).

Novavax Says European Commission Granted Marketing Authorization For Updated 2024-2025 Nuvaxovid COVID-19 Vaccine

Novavax said it is aware of an analyst report published on October 1, 2024, which referred to discussions with Novavax&rsquo;s management regarding, among other things, the anticipated U.S. market for COVID-19 vaccination for the 2024-2025 vaccination season.&nbsp;

Novavax Clarifies That While It Has Anticipated COVID-19 Vaccination Market In US Will Be Similar To Last Year, It Has Neither Updated Nor Reaffirmed FY24 Financial Guidance Issued On August 8 - Filing

Jefferies analyst Roger Song maintains Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) with a Buy and maintains $31 price target.

Jefferies Maintains Buy on Novavax, Maintains $31 Price Target

Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) has outperformed the market over the past 5 years by 10.54% on an annualized basis producing an average annual return of 25.09%. Currently, Novavax has a market capitalization of $2.32 billion. 
Buying $1000 In NVAX: If an investor had bought $1000 of NVAX stock 5 years ago, it would be worth $2,898.22 today based on a price of $14.52 for NVAX at the time of writing.
<h3>Novavax's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727894019_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Novavax 5 Years Ago Would Be Worth Today

U.S. stocks were slightly higher, with the Dow Jones index gaining around 0.2% on Wednesday.
Shares of RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) rose sharply during Monday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/RPM/earnings">first-quarter adjusted EPS results</a>.
Sales declined 2.1% Y/Y to $1.97 billion, missing the consensus of $2.015 billion. Adjusted EPS was $1.84, beating the consensus of $1.75.
RPM shares jumped 7.2% to $128.71 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 21.6% to $3.88.</li>
<li>UP Fintech Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) gained 20% to $7.46. Shares of US-listed Chinese stocks traded higher on continued strength following recent stimulus measures and the start of the National Day Golden Week.</li>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) gained 19.4% to $5.73 after the company announced that Toyota will invest an additional $500 million to support the certification and commercial production of the electric air taxi.</li>
<li>AMTD Digital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HKD#NYSE">HKD</a>) climbed 17.1% to $3.7473.</li>
<li>Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) gained 12% to $3.1113.</li>
<li>Talkspace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TALK#NASDAQ">TALK</a>) surged 12% to $2.3650.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) climbed 10.7% to $9.52.</li>
<li>Great Lakes Dredge &amp; Dock Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLDD#NASDAQ">GLDD</a>) climbed 9.7% to $11.76 after the company announced the receipt of several dredging awards totaling $342.3 million.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) gained 9.3% to $13.47.</li>
<li>Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) rose 6.5% to $65.44. Ciena announced a $1 billion share repurchase authorization.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41141371/levi-strauss-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-">Levi Strauss Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Intraday Update

CIEN

CLOV

GLDD

JOBY

OKLO

TALK

TIGR

RPM International Posts Upbeat Earnings, Joins Joby Aviation, Ciena And Other Big Stocks Moving Higher On Wednesday

Global

World Organization For Animal Health Says Hungary And Italy Report Farm Outbreaks Of Highly Pathogenic H5N1 Bird Flu

Novavax's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NYSE">NVAX</a>) short percent of float has risen 6.09% since its last report. The company recently reported that it has 33.53 million shares sold short, which is 26.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Novavax Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727789422_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novavax has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Novavax's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Novavax's peer group average for short interest as a percentage of float is 13.61%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Novavax's Recent Short Interest

Macro Economic Events

Economics

World Organization For Animal Health Says Germany Reports Outbreak Of Highly Pathogenic H5N1 Bird Flu On Farm In Eastern Part Of The Country

<a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/novavax.html" title="https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/novavax.html">https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/novavax.html</a>

Reported September 23; Health Canada Approves Novavax Nuvaxovid And XBB.1.5 Omicron Subvariant COVID-19 Vaccines For Primary And Booster Doses

Novavax cools after clarifying analyst report on COVID vaccine market

Novavax: Lack Of Sustainable Revenue Growth Is A Problem

Novavax gets EU authorization for updated COVID-19 vaccine

Novavax (NVAX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mayank Mamtani from B.Riley ...

Buy Rating Affirmed for Novavax Amid Strategic Alliances and Promising Vaccine Trials

Novavax stock plunges as FDA puts clinical hold on COVID-flu combo vaccine

Novavax ( ($NVAX) ) just unveiled an update. Novavax faces a clinical hold from the FDA on its COVID-19-Influenza Combination and standalone influe...

Novavax Faces FDA Hold Amid Vaccine Trials

Biggest stock movers Wednesday: NVAX, UAL, ASML, JBHT, and more

Jefferies analyst Roger Song has maintained their bullish stance on NVAX stock, giving a Buy rating on October 10. Roger Song has given his Buy rat...

Cautious Optimism for Novavax Amid Clinical Hold Challenges

Shares of pharmaceutical company Novavax ($NVAX) are down 18% on news that the U.S. Food and Drug Administration (FDA) has halted one of the compan...

Novavax (NASDAQ:NVAX) Stock Drops 18% as Clinical Trial Halted

Novavax (NASDAQ:NVAX) Stock Drops 18% after Clinical Trial Is Halted

ASML

BNTX

IBKR

JBHT

MRNA

Press Releases

Novavax Submits Application to Health Canada for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024

Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights

Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

Novavax to Participate in Upcoming September Conferences

Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S.

Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development

Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU

Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Comments

Novavax

Intérêt court

Novavax (NASDAQ:NVAX) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL